Sagimet's Denifanstat Shows Promise in Treating Fatty Liver Disease
TL;DR Summary
Sagimet Biosciences announces positive topline results from its Phase 2b FASCINATE-2 clinical trial of denifanstat, a fatty acid synthase inhibitor, in NASH patients with stage 2 or 3 fibrosis. The trial showed statistically significant improvements in NASH resolution, fibrosis reduction, and liver health markers compared to placebo. Denifanstat was generally well-tolerated, with no treatment-related serious adverse events observed. The company plans to advance to Phase 3 development and aims to start in the second half of 2024.
Topics:business#clinical-trial#denifanstat#fatty-acid-synthase-inhibitor#health#nash#sagimet-biosciences
- Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH GlobeNewswire
- Sagimet stock doubles as phase 2b MASH trial hits primary goals, despite dropout queries FierceBiotech
- Drug Reduces Fatty Liver Disease Symptoms in Trial Newsmax
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
8 min
vs 8 min read
Condensed
95%
1,579 → 77 words
Want the full story? Read the original article
Read on GlobeNewswire